Comparison of the efficacy and tolerability of topically administered @entity24174 , XXXX and placebo in the treatment of @entity56 and rhino- @entity2024 .

@entity1 @entity9992 @entity1989 @entity24174 @entity1109 @entity56 @entity2024 @entity3917
OBJECTIVE AND SETTING: @entity24174 (AZE) in a novel, eye drop, formulation, was compared with topically applied @entity9992 (SCG) and placebo (PLA) in the treatment of @entity56 or rhino- @entity2024 in a multicentre, parallel group study. RESEARCH DESIGN: 144 subjects ranging in age from 16 to 65 years participated. All had at least a 2-year history of @entity56 and were symptomatic at the time of inclusion. Medications were administered topically either twice daily (AZE/ @entity1989 ) or four times daily (SCG) over a 2-week treatment period. Method and outcome measures: @entity24174 and placebo were compared double-blind; the comparison versus SCG was carried out in an open manner. Itching, redness, flow of tears, eyelid swelling, @entity1109 , @entity3917 , soreness and discharge were scored on a 4-point severity scale. RESULTS: Results for the decrease of main @entity2024 symptoms (itching, tearing and conjunctival redness) showed a marked effect for both active treatments on day 3 with a sustained improvement on days 7 and 14. A clear response to treatment (an improvement of sum scores for day 3 of >/=3 points compared to baseline) occurred in 85.4% of @entity24174 -treated @entity1 , 83.0% of @entity9992 @entity1 and 56.3% of placebo @entity1 . Response rates for both active treatments were statistically superior to those for placebo ( @entity24174 p = 0.005; @entity9992 p = 0.007). Global assessment of efficacy was at least 'satisfactory' for 90.0% of @entity24174 @entity1 , 81.3% of @entity9992 @entity1 and 66.3% of placebo-treated @entity1 . The most frequent adverse effects were transient application site reactions which tended to disappear with increasing duration of treatment, and, less frequently, taste perversion. CONCLUSION: The results of this study indicate that the therapeutic use of @entity24174 eye drops in @entity1 with @entity56 or rhino- @entity2024 can be recommended.
